LeMaitre Vascular Inc (LMAT) reported strong financial results for the second quarter of 2025, beating analysts' expectations. Earnings per share (EPS) came in at $0.60, compared to the forecast of $0.57. This positive earnings surprise of 5.26% was accompanied by actual revenue of $64.2 million, which exceeded the expected $62.48 million by 2.75%. In response, the company's share price rose by 1.47% to close at $84.36 in after-hours trading.
Key figures
Earnings per share (EPS) of $0.60 beat forecasts by 5.26%.
Sales of $64.2 million exceeded expectations by 2.75%.
Share price rose 1.47 % in after-hours trading.
Gross margin improved by 110 basis points to 70%.
Annual sales forecast raised to $251m.
What does LeMaitre actually do?
LeMaitre Vascular is a medical technology company specializing in the development, manufacture and marketing of devices, implants and services for the treatment of peripheral vascular diseases. It offers solutions for various areas of vascular surgery, such as carotid surgery, dialysis access, peripheral bypass surgery and endovascular aneurysm therapy.
LeMaitre Vascular is a global leader and innovator in this field, offering its products in over 90 countries, both directly and through distributors. The company was founded in 1986 and is headquartered in Burlington, Massachusetts.
In summary, LeMaitre Vascular is focused on the development and delivery of medical products and services that support and enhance the treatment of peripheral vascular disease.
